Session: MON 238-262-Vitamin D Action, Deficiency & Disorders
Bench to Bedside
Poster Board MON-246
Materials and methods: Using a case-control design, we measured serum 25(OH)D levels on pregnant women receiving care after 20 weeks of gestation at Dhaka Medical College Hospital in Bangladesh with preeclampsia (n=33), eclampsia (n=79) and normal pregnancy (controls, n=76). The patients with prior medical history of renal insufficiency, seizure disorder or essential hypertension were excluded from the study. Information about maternal age, BMI, maternal education, smoking status during pregnancy and the use of multivitamin in the last trimester of pregnancy was obtained. Odds of developing preeclampsia and eclampsia with vitamin D deficiency were calculated using logistic regression analysis.
Results:The prevalence of vitamin D insufficiency was very high in our study subjects with more than three quarters (78%) of all pregnant women having a serum 25(OH)D level <30 ng/ml. The mean serum 25(OH)D level was 24.86 ng/ml in controls, 23.96 ng/ml in preeclamptic women, and 21.56 ng/ml in eclampsia patients. Comparing to those who had a serum 25(OH)D level of >=30 ng/ml, the odds ratio (95% CI) of developing preeclampsia and eclampsia in mothers with vitamin D insufficiency were 3.9 (95% CI=1.18-12.87) and 5.14 (95% CI=1.98-13.37), respectively (adjusting for age, BMI and duration of pregnancy). When vitamin D was analyzed as a continuous variable, we estimated that with every 10 ng/ml decrease in serum 25(OH)D level, the adjusted risks of developing preeclampsia and eclampsia increased by 1.66 (95% CI=1.05-3.02) and 2.42 times (95% CI=1.54-3.82), respectively.
Conclusions: The odds of developing preeclampsia and eclampsia are increased by up to 3-5 folds with vitamin D insufficiency. Since preeclampsia and eclampsia can lead to serious complications for both mother and the offspring, vitamin D may be safely supplemented during pregnancy in high risk populations to decrease these adverse consequences.
Nothing to Disclose: MIU, CAK, ST, SR, LS
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters